10月16日，迈威生物盘中上涨2.18%，截至10:16，报48.25元/股，成交2.26亿元，换手率2.34%，总市值 192.81亿元。 资金流向方面，主力资金净流入781.04万元，特大单买入1292.29万元，占比5.71%，卖出1211.61万元， 占比5.35%；大单买入5781.67万元，占比25.53%，卖出5081.31万元，占比22.44%。 迈威生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、抗癌药物、抗 癌治癌、创新药、眼科概念等。 截至6月30日，迈威生物股东户数1.79万，较上期增加11.66%；人均流通股11379股，较上期减少 10.44%。2025年1月-6月，迈威生物实现营业收入1.01亿元，同比减少12.43%；归母净利润-5.51亿元， 同比减少23.90%。 机构持仓方面，截止2025年6月30日，迈威生物十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股474.26万股，为新进股东。兴全合润混合A（163406）位居第五大流通股东，持股339.00 万股，为新进股东。鹏华医药科技股票A（001230）位居第六大流通股东，持股 ...

Core Viewpoint - The innovative drug concept stocks experienced a significant surge in early trading on October 15, with several companies reaching their daily price limits and notable increases in stock prices [1]. Group 1: Stock Performance - Angli康 reached the daily limit up, indicating strong investor interest [1]. - Guangshengtang saw a rise of over 10%, with a notable increase of 14.41% in its stock price [2]. - Other companies such as Saili Medical, Shutaishen, Rongchang Bio, and Lianhuan Pharmaceutical also experienced substantial gains, contributing to the overall positive trend in the innovative drug sector [1]. Group 2: Notable Stock Increases - Guangshengtang (300436) reported a stock increase of 116.94%, with a rise of 14.41% [2]. - Pinlikang (002940) increased by 41.20%, with a rise of 10.01% [2]. - Saili Medical (603716) saw a 27.12% increase, with an 8.35% rise [2]. - Shutaishen (300204) experienced a 34.77% increase, with a 7.88% rise [2]. - Jimin Health (603222) rose by 10.64%, with a 6.72% increase [2]. - Lianhuan Pharmaceutical (600513) increased by 20.21%, with a 6.37% rise [2]. - Rongchang Bio (688331) saw a 97.06% increase, with a 6.31% rise [2]. - Zhendong Pharmaceutical (300158) increased by 6.95%, with a 5.95% rise [2]. - Kangchen Pharmaceutical (035500) rose by 48.68%, with a 4.91% increase [2]. - Maiwei Niwu-U (688062) saw a 46.58% increase, with a 4.86% rise [2].

资料显示，迈威(上海)生物科技股份有限公司位于中国(上海)自由贸易试验区蔡伦路230号2幢105室香港 铜锣湾希慎道33号利园1期19楼1928室，成立日期2017年5月12日，上市日期2022年1月18日，公司主营 业务涉及治疗用生物制品的研发、生产与销售。主营业务收入构成为：销售商品99.91%，提供劳务 0.09%。 10月15日，迈威生物盘中上涨2.05%，截至10:03，报45.33元/股，成交1.10亿元，换手率1.20%，总市值 181.14亿元。 资金流向方面，主力资金净流入607.26万元，特大单买入613.51万元，占比5.57%，卖出235.49万元，占 比2.14%；大单买入3098.47万元，占比28.13%，卖出2869.24万元，占比26.05%。 迈威生物今年以来股价涨124.41%，近5个交易日跌7.72%，近20日跌9.74%，近60日涨46.94%。 今年以来迈威生物已经5次登上龙虎榜，最近一次登上龙虎榜为9月2日。 迈威生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、抗癌治癌、抗 癌药物、眼科概念、创新药等。 截至6月30日，迈威生物股东户 ...

Core Viewpoint - The company, Maiwei (Shanghai) Biotechnology Co., Ltd., announced the presentation of clinical research data for its antibody-drug conjugate 7MW3711 at the 2025 European Society for Medical Oncology (ESMO) conference, highlighting its potential in treating advanced solid tumors with promising efficacy and safety profiles [1][2][3]. Group 1: Drug Overview - 7MW3711 is an antibody-drug conjugate targeting B7-H3, designed for advanced malignant solid tumors, with B7-H3 being overexpressed in many cancer types but low in normal tissues [2][3]. - The drug exhibits structural stability, high purity, and ease of industrial scaling, utilizing a novel camptothecin-based toxin that shows superior anti-tumor activity compared to similar drugs [3][4]. - The clinical trial data presented at ESMO indicates that among 54 evaluable patients receiving a dose of 4.0 mg/kg or higher, 19 patients achieved partial or complete responses [1][4]. Group 2: Clinical Trial Results - As of September 15, 2025, a total of 74 patients were enrolled in the I/II phase clinical study, with no dose-limiting toxicities observed and the maximum tolerated dose not yet reached [3][4]. - In the 4.0 mg/kg or higher dose group, the objective response rate (ORR) for esophageal cancer patients was 42.9%, with a disease control rate (DCR) of 100% [1][4]. - For lung cancer patients in the same dose group, the ORR for small cell lung cancer (SCLC) and squamous non-small cell lung cancer (Sq-NSCLC) was 50.0% and 38.5%, respectively, with DCRs of 90.0% and 92.3% [1][4].

证券日报网讯 10月13日晚间，迈威生物发布公告称，近日，公司收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，注射用7MW4911的临床试验获得批准。 （文章来源：证券日报） ...

格隆汇10月13日丨迈威生物(688062.SH)公布，公司收到国家药品监督管理局核准签发的《药物临床试 验批准通知书》，注射用7MW4911的临床试验获得批准。7MW4911采用高度工程化设计，整合三大核 心元件：具有快速内化特性及跨物种（人/猴）中等亲和力的CDH17高特异性单抗Mab0727、新型可裂 解连接子、以及为克服多药耐药机制设计的专有DNA拓扑异构酶I抑制剂MF-6载荷。MF-6通过卓越的 血浆稳定性、可控的药物释放及强效旁观者效应，显著增强抗肿瘤活性。 ...

7MW4911是基于公司自主知识产权的IDDC™抗体偶联技术平台开发的靶向钙黏蛋白17(CDH17)的创新 抗体偶联药物(ADC)。CDH17作为经泛癌种多组学验证的潜力治疗靶点，在正常组织中局限于肠上皮基 底外侧膜表达，而在结直肠癌、胃癌及胰腺癌等消化道恶性肿瘤中呈现显著过表达，其异常高表达与肿 瘤侵袭转移及不良预后密切相关，为精准干预提供了理想靶点。 智通财经APP讯，迈威生物(688062.SH)发布公告，近日，公司收到国家药品监督管理局核准签发的 《药物临床试验批准通知书》，注射用7MW4911的临床试验获得批准。 ...

Core Viewpoint - The announcement indicates that Maiwei Biotech (688062.SH) has received approval from the National Medical Products Administration for the clinical trial of its innovative antibody-drug conjugate (ADC) 7MW4911, targeting CDH17, a promising therapeutic target in various cancers [1] Company Summary - Maiwei Biotech has developed 7MW4911 based on its proprietary IDDC antibody conjugation technology platform [1] - The ADC targets calcium adhesion protein 17 (CDH17), which is significantly overexpressed in colorectal cancer, gastric cancer, and pancreatic cancer, making it an ideal target for precise intervention [1] Industry Summary - CDH17 has been validated as a potential therapeutic target through multi-omics studies across various cancer types, indicating its relevance in cancer treatment [1] - The abnormal high expression of CDH17 is closely associated with tumor invasion, metastasis, and poor prognosis, highlighting its importance in oncology [1]

Group 1 - The core point of the article is that Maiwei Biotech has received approval from the National Medical Products Administration for the clinical trial of its injectable drug 7MW4911 [1] - Maiwei Biotech's revenue composition for the year 2024 is projected to be 99.92% from the pharmaceutical manufacturing industry and 0.08% from other businesses [1] - As of the report, Maiwei Biotech has a market capitalization of 17.7 billion yuan [1]

Core Viewpoint - Maiwei Biotech (688062) has received approval from the National Medical Products Administration for the clinical trial of its injectable drug 7MW4911 for advanced solid tumors [1] Group 1 - The company announced the receipt of the clinical trial approval notice on October 13 [1] - The approval allows the company to proceed with clinical trials for 7MW4911, which targets advanced solid tumors [1]